PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756

Synapse

Volumn 32, Issue 2, 1999, Pages 93-109

  Abi Dargham, Anissa ^a   Simpson, Norman ^a   Kegeles, Lawrence ^a   Parsey, Ramin ^a   Hwang, Dah Ren ^a   Anjilvel, Satish ^a   Zea Ponce, Yolanda ^a   Lombardo, Ilise ^a   Van Heertum, Ronald ^a   Mann, John J ^a   Foged, Christian ^b   Halldin, Christer ^c   Laruelle, Marc ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NOVO NORDISK A S   (Denmark)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Benzazepine; Binding competition; Dopamine; D1 receptors; Positron emission tomography

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8 CHLORO 5 (2,3 DIHYDROBENZOFURAN 7 YL) 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPIN 7 OL; AMPHETAMINE; CARBON 11; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; RACLOPRIDE; TRACER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BABOON; BOLUS INJECTION; COMPARTMENT MODEL; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG COMPETITION; DRUG RECEPTOR BINDING; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; AMPHETAMINE; ANIMALS; BENZAZEPINES; BENZOFURANS; BINDING, COMPETITIVE; BRAIN CHEMISTRY; CARBON RADIOISOTOPES; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; FEMALE; MAGNETIC RESONANCE IMAGING; MALE; PAPIO; RACLOPRIDE; RECEPTORS, DOPAMINE D1; SALICYLAMIDES; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033560699     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199905)32:2<93::AID-SYN3>3.0.CO;2-C     Document Type: Article

References (85)

1. 123I]iomazenil: kinetic and equilibrium paradigms. J Nucl Med 35:228-238.
2. Abi-Dargham A, Zea-Ponce Y, Terriere D, Al-Tikriti M, Baldwin R, Hoffer P, Charney D, Leysen JE, Laruelle M, Mertens J, Innis RB. 1997. Preclinical evaluation of [I-123]R93274 as a SPECT radiotracer for imaging serotonin 5-HT2A receptors. Eur J Pharmacol 321:285-293.
3. Abi-Dargham A, Gil R, Krystal J, Baldwin R, Seibyl J, Bowers M, van Dyck C, Charney D, Innis R, Laruelle M. 1998. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767.
4. 1 receptor antagonists. Eur J Pharmacol 219:45-52.
5. 1A dopamine receptor staining. Synapse 27:313-321.
6. 2 dopamine receptors in human Y-79 retinoblastoma cells. Mol Pharmacol 39:650-658.
7. Booij J, Korn P, Linszen DH, vanRoyen EA. 1997. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 24:674-677.
8. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, deBartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D. 1997. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569-2574.
9. 125I] IBZM): a potential imaging ligand for D-2 dopamine receptors in SPECT. Life Sci 42:2097-2104.
10. 1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation. Brain Res 730: 17-31.
11. Carson RE. 1986. Parameters estimation in positron emission tomography. In: Phelps ME, Mazziotta JC, Schelbert HR, editors. Positron emission tomography. Principles and applications for the brain and the heart. New York: Raven Press. p 347-390.
12. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, Herscovitch P. 1993. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13:24-42.
13. Carson RE, Breier A, deBartolomeis A, Saunders RC, Su TP, Schmall B, Der MG, Pickar D, Eckelman WC. 1997. Quantification of amphetamine-induced changes in [C-11]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 17:437-447.
14. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
15. 1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093-1102.
16. Dewey SL, Brodie JD, Fowler JS, MacGregor RR, Schyler DJ, King PT, Alexoff DL, Volkow ND, Shiue CY, Wolf AP, Bendriem B. 1990. Positron emission tomography (PET) studies of dopamine/cholinergic interaction in the baboon brain. Synapse 6:321-327.
17. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13:350-356.
18. 1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists. J Neurosci 18:1650-1661.
19. Endres CJ, Kolachana BS, Saunders RC, Su T, Weinberger D, Breier A, Eckelman WC, Carson RE. 1997. Kinetic modeling of [C-11]raclopride: combined PET-microdialysis studies. J Cereb Blood Flow Metab 17:932-942.
20. 2 dopamine receptor binding in the living human brain by PET. Science 231:258-261.
21. Farde L, Halldin C, Stone-Elander S, Sedvall G. 1987. PET analysis of human dopamine receptors subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology 92:278-284.
22. 2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptic. Psychopharmacology 99:S28-S31.
23. 11C-carfentanil binding to opiate receptors in human measured by positron emission tomography. J Cereb Blood Flow Metab 9:398-409.
24. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. 1994. Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers: β-CIT, IBF and iomazenil. J Pharm Sci 83:1014-1019.
25. Gifford AN, Gatley SJ, Ashby CR. 1996. Endogenously released dopamine inhibits the binding of dopaminergic PET and SPECT ligands in superfused rat striatal slices. Synapse 22:232-238.
26. Grady EF, Bohm SK, Bunnett NW. 1997. Turning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors. Am J Physiol 273:G586-601.
27. Graham MM, Lewellen BL. 1993. High-speed automated discrete blood sampling for positron emission tomography. J Nucl Med 34:1357-1360.
28. Hall H, Farde L, Sedvall G. 1988. Human dopamine receptors subtypes - in vitro binding analysis using [3H]SCH 23390 and [3H]raclopride. J Neural Transm 73:7-21.
29. 2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11:245-256.
30. 1 receptors using positron emission tomography. Appl Radiat Isot 37:1039-1043.
31. Halldin C, Farde L, Barnett A, Sedvall G. 1991. Synthesis of carbon-11 labelled SCH 39166, a new selective dopamine D-1 receptor ligand, and preliminary PET investigations. Int J Radiat Appl Instrum [a] 42:451-455.
32. 11C]NNC 756, dopamine D-1 receptor ligands. Preparation, autoradiography and PET investigation in monkey. Nucl Med Biol 8:945-953.
33. 2 dopamine receptors. J Nucl Med 36:1275-1281.
34. 1-dopamine receptor. J Nucl Med 39:2061-2068.
35. Hartvig P, Torstenson R, Tedroff J, Watanabe Y, Fasth KJ, Bjurling P, Langstrom B. 1997. Amphetamine effects on dopamine release and synthesis rate studied in the rhesus monkey brain by positron emission tomography. J Neural Transm 104:329-339.
36. 2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci 15:5222-5237.
37. 2 receptor in non-human primates. Synapse 10:177-184.
38. Inoue O, Kobayashi K, Tsukada H, Itoh T, Langstrom B. 1991. Difference in in vivo receptor binding between [3H]N-methylspiperone and [3H]raclopride in reserpine-treated mouse brain. J Neural Transm Gen Sect 85:1-10.
39. Ito H, Nyberg S, Halldin C, Lundvist C, Farde L. 1998. PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. J Nucl Med 39:208-214.
40. 1-dopamine receptor. Psychopharmacology 113:149-156.
41. 2 receptors. Synapse 15:169-176.
42. Koenig JA, Edwardson JM. 1997. Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci 18:276-287.
43. Koeppe RA, Frey KA, Kume A, Albin R, Kilbourn MR, Kuhl DE. 1997. Equilibrium versus compartmental analysis for assessment of the vesicular monoaraine transporter using (+)-alpha-[C-11]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab 17:919-931.
44. Kuczenski R, Segal D. 1989. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci 9:2051-2065.
45. Rung M-P, Kung HF, Billings J, Yang Y, Murphy RA, Alavi A. 1990. The characterization of IBF as a new selective dopamine D-2 receptor imaging agent. J Nucl Med 31:648-654.
46. 1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756. J Nucl Med 35:1916-1920.
47. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, Frackowiak RS. 1996. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 16:42-52.
48. Laruelle M, Sidhu A, Casanova MF, Weinberger DR, Kleinman JE. 1991. Characterization of [125I]SCH23982 binding in human brain: comparison with [3H]SCH23390. Neurosci Lett 31:273-276.
49. 123I]iomazenil binding to benzodiazepine receptors in nonhuman primates. II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab 14:453-465.
50. 123I]iodobenzofuran and single photon emission computerized tomography. Eur J Pharmacol 263:39-51.
51. Laruelle M, Baldwin RM, Rattner Z, Al-Tikriti MS, Zea-Ponce Y, Zoghbi SS, Charney DS, Price JC, Frost JJ, Hoffer PB, Innis RB. 1994c. SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates. I. Kinetic modeling of single bolus experiments. J Cereb Blood Flow Metab 14:439-452.
52. 2 receptors in healthy subjects. J Nucl Med 35:743-754.
53. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB. 1995. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36:1182-1190.
54. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, De Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. 1996. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235-9240.
55. Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, Seibyl JP, Zoghbi SS, Bowers MB, Jatlow P, Charney DS, Innis RB. 1997a. Imaging D-2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17:162-174.
56. Laruelle M, Iyer RN, Al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW. 1997b. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1-14.
57. Levenberg K. 1944. A method for the solution of certain problems in least squares. Q Appl Math 2:164-168.
58. 2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci USA 90:8861-8865.
59. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740-747.
60. 2 dopamine receptors in caudate-putamen of nonhuman primates (Macaca fascicularis). J Neurochem 51:934-943.
61. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. 1984. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15:217-227.
62. Mukherjee J, Yang ZY, Das MK, Brown T. 1995. Fluorinated benzamide neuroleptics. III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)-methyl]-5-(3-[18F]fluoropropyl)-2,3- dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol 22:283-296.
63. Mukherjee J, Yang ZY, Lew R, Brown T, Kronmal S, Cooper MD, Seiden LS. 1997. Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, F-18-fallypride in nonhuman primates using positron emission tomography. Synapse 27:1-13.
64. Pardridge WM. 1997. Drug delivery to the brain. J Cereb Blood Flow Metab 17:713-731.
65. Pellizzari CA, Chen GTY, Spelbring DR, Weichselbaum RR. 1989. Accurate three-dimensional registration of CT, PET, and/or MR images of the brain. J Comput Assist Tomogr 8:20-26.
66. Price JC, Mason S, Lopresti B, Holt D, Simpson NR, Drevets W, Smith GS, Mathis CA. 1997. PET measurements of endogenous neurotransmitter activity using high and low affinity radiotracers. Neuroimage 5:B77.
67. Ross SB. 1991. Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism. J Neurochem 56:22-29.
68. Ross SB, Jackson DM. 1989a. Kinetic properties of the in vivo accumulation of the dopamine D-2 receptor antagonist raclopride in the mouse brain in vivo. Naunyn Schmiedeberg Arch Pharmacol 340:6-12.
69. 3H](-)-N-n-propylnorapomorphine in the mouse brain. Naunyn Schmiedeberg Arch Pharmacol 340:13-20.
70. Schlaepfer TE, Pearlson GD, Wong DF, Marenco S, Dannals RF. 1997. PET study of competition between intravenous cocaine and [C-11]raclopride at dopamine receptors in human subjects. Am J Psychiatry 154:1209-1213.
71. 1 receptor binding in the monkey brain using PET. Psychopharmacology 103:150-153.
72. Seeman P. 1993. Receptor tables. Vol. 2: Drug dissociation constants for neuroreceptors and transporters. Toronto: SZ Research.
73. Seeman P, Van Tol HH. 1994. Dopamine receptor pharmacology. Trends Pharmacol Sci 15:264-270.
74. 3H]raclopride: implications for positron emission tomography of the human brain. Synapse 3:96-97.
75. Sharp T, Zetterstrom T, Ljungberg T, Ungerstedt U. 1987. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res 401:322-330.
76. 1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines. Proc Natl Acad Sci USA 91:5720-5724.
77. Snyder WS, Cook MI, Karhausen LR, Nasset ES, Howells GP, Tipton IH. 1984. Central nervous system. In: Report of the task group on reference man. New York: Pergamon Press. p 281.
78. Van der Werf JF, Sebens JB, Vaalburg W, Korf J. 1986. In vivo binding of N-n-propylnorapomorphine in the rat brain: regional localization, quantification in striatum and lack of correlation with dopamine metabolism. Eur J Pharmacol 87:259-270.
79. Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schyler D, MacGregor R, Logan J, Alexoff D, Shea C, Hitzemann R, Angrist B, Wolf AP. 1993. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 34:609-613.
80. 11C]raclopride in the human brain. Synapse 16:255-262.
81. Volkow ND, Wang GJ Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, Dewey SL, Pappas N. 1997. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386:830-833.
82. Wienhard K, Eriksson L, Grootoonk S, Casey M, Pietrzyk U, Heiss WD. 1992. Performance evaluation of the positron scanner ECAT EXACT. J Comput Assist Tomogr 16:804-13.
83. Woods RP, Cherry SR, Mazziotta JC. 1992. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 16(4):620-633.
84. 3H]raclopride binding in the rat brain. Synapse 9:188-194.
85. 2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 65:709-730.